For many people living with hemophilia with inhibitors, the 8 mg vial will allow for faster reconstitution “ the time it takes to prepare the injection “ than their current NovoSeven?® RT regimen. Those who previously had to use three vials to deliver an 8 mg dose will now have to reconstitute only one vial. Though the amount of powder in the 8 mg vial is larger than the 5 mg vial, the vial will be the same size and will have a yellow cap to distinguish it from the smaller dose.

"We have heard from patients and physicians alike that when they are treating a bleed, every second counts. We at Novo Nordisk are committed to improving the lives of people living with hemophilia with inhibitors," said Eddie Williams, Vice President, Biopharmaceuticals, at Novo Nordisk. "The NovoSeven?® RT 8 mg vial will allow patients to get the medicine they need much faster when experiencing a bleed, without having to manage multiple vials. We're also pleased that it will have a positive environmental impact as well “ fewer vials may mean less waste."

The new vial size is expected to be available by November.

The enhanced stability of all vial sizes will allow for more flexibility when managing treatment supplies “ another important aspect of hemophilia treatment.

SOURCE Novo Nordisk